Surya Pharmaceutical has received certificate of suitability (COS) for Cefalexin Monohydrate from European Directorate for the Quality of Medicines (EDQM), in addition to already approved Cefixime.
Further, the company's Banur plant has also been approved by Teva for the supply of Intermediates. These developments and the expected approvals from USFDA/TGA/MCA/MCC will help the company service its debt obligation post restructuring.
Besides, the State Bank of India as the lead bank of the consortium of bankers of Surya Pharmaceutical has referred the company for restructuring of its debt to the corporate debt restructuring cell, Mumbai and the company has been admitted by CDR Cell with the support of majority of lenders.
Surya Pharmaceutical is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |